Proactive Investors
27 Jul 2026, 14:52 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
FDA reviewers raised concerns regarding the effectiveness and scientific justification of Capricor Therapeutics' deramiocel for DMD-associated cardiomyopathy. — Negative FDA briefing documents significantly increase the likelihood of a CRL (Complete Response Letter) or rejection, as evidenced by the 67% share price drop.
-0.90The FDA questioned Capricor's decision to switch primary assessment metrics from raw scores to percentage changes and from ejection fraction measurements to patient ranking. — Questioning the integrity of data analysis suggests potential 'p-hacking' or manipulation to achieve significance, which undermines investor confidence in trial results.
-0.70FDA staff expressed doubt over whether trial participants actually had DMD-related cardiomyopathy and if the therapy reached the heart in sufficient quantities. — Doubts regarding the patient population and drug delivery mechanism call into question the fundamental clinical utility of the product.
-0.60Continue reading
6 related stories
Search tags
Zephyr Energy PLC has entered a letter of intent for up to US$15 million in pre-production financing from Atlas Commodity Markets for the Paradox Project. — Securing pre-production financing is a positive development for project advancement and liquidity for a small-cap energy firm.
+0.30Which stocks this story touches
Shares plummeted 67% after FDA reviewers raised significant concerns regarding the efficacy and data analysis of its experimental therapy.
CEO discussed a 'seminal' letter of intent for up to $15 million in pre-production financing for the Paradox Project.
Mentioned only as a provider of existing treatments for DMD, with no news affecting its specific valuation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
9h ago
